AN2 Therapeutics Dirección
Dirección controles de criterios 3/4
Actualmente no disponemos de información suficiente sobre el CEO.
Información clave
Eric Easom
Chief Executive Officer (CEO)
US$3.3m
Compensación total
| Porcentaje del salario del CEO | 17.2% |
| Permanencia del CEO | 5yrs |
| Participación del CEO | 4.2% |
| Permanencia media de la dirección | 3.6yrs |
| Promedio de permanencia en la Junta Directiva | 4.8yrs |
Actualizaciones recientes de la dirección
Recent updates
We're Keeping An Eye On AN2 Therapeutics' (NASDAQ:ANTX) Cash Burn Rate
Nov 21
Is AN2 Therapeutics (NASDAQ:ANTX) In A Good Position To Invest In Growth?
Jul 04Here's Why We're Not Too Worried About AN2 Therapeutics' (NASDAQ:ANTX) Cash Burn Situation
Mar 23AN2 Therapeutics (NASDAQ:ANTX) Is In A Good Position To Deliver On Growth Plans
Dec 05AN2 Therapeutics (NASDAQ:ANTX) Is In A Good Position To Deliver On Growth Plans
Aug 20We Think AN2 Therapeutics (NASDAQ:ANTX) Can Afford To Drive Business Growth
May 09We're Not Very Worried About AN2 Therapeutics' (NASDAQ:ANTX) Cash Burn Rate
Feb 03We're Hopeful That AN2 Therapeutics (NASDAQ:ANTX) Will Use Its Cash Wisely
Oct 21AN2 Therapeutics secures $17.8M contract from NIH
Sep 29We Think AN2 Therapeutics (NASDAQ:ANTX) Can Afford To Drive Business Growth
Jul 01Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$61m |
| Jun 30 2024 | n/a | n/a | -US$65m |
| Mar 31 2024 | n/a | n/a | -US$66m |
| Dec 31 2023 | US$3m | US$575k | -US$65m |
| Sep 30 2023 | n/a | n/a | -US$60m |
| Jun 30 2023 | n/a | n/a | -US$54m |
| Mar 31 2023 | n/a | n/a | -US$49m |
| Dec 31 2022 | US$3m | US$481k | -US$43m |
| Sep 30 2022 | n/a | n/a | -US$40m |
| Jun 30 2022 | n/a | n/a | -US$38m |
| Mar 31 2022 | n/a | n/a | -US$35m |
| Dec 31 2021 | US$2m | US$377k | -US$28m |
Compensación vs. Mercado: La compensación total de Eric($USD3.34M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD649.63K).
Compensación vs. Ingresos: La compensación de Eric ha sido consistente con los resultados de la empresa en el último año.
CEO
Eric Easom (56 yo)
5yrs
Permanencia
US$3,342,848
Compensación
Mr. Eric E. Easom is Co-founder of AN2 Therapeutics, Inc. and has been its CEO, President & Director from November 19, 2019 and is its Chairman of the Board since June 2024. He served as Senior Director of...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Co-Founder | 5yrs | US$3.34m | 4.23% $ 1.7m | |
| Co-Founder & Chairman of the Board | 7.5yrs | US$179.64k | 1.69% $ 675.5k | |
| CFO, Principal Financial Officer & Principal Accounting Officer | 5yrs | US$1.52m | 0.010% $ 4.2k | |
| Co-Founder & Senior Clinical Advisor | no data | sin datos | sin datos | |
| Co-Founder | no data | sin datos | sin datos | |
| Chief Legal Officer & COO | 2.2yrs | US$1.66m | sin datos | |
| Chief Development Officer | 5yrs | sin datos | 0.0025% $ 983.7 | |
| Chief Strategy Officer | no data | sin datos | 0.026% $ 10.3k | |
| Senior VP of Research & Head of Chemistry | no data | sin datos | sin datos |
3.6yrs
Permanencia media
60.5yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de ANTX se considera experimentado (3.6 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Co-Founder | 5yrs | US$3.34m | 4.23% $ 1.7m | |
| Co-Founder & Chairman of the Board | 7.5yrs | US$179.64k | 1.69% $ 675.5k | |
| Independent Director | 2.8yrs | US$145.64k | 0% $ 0 | |
| Independent Director | 3.6yrs | US$153.14k | 0% $ 0 | |
| Lead Independent Director | 2.5yrs | US$142.14k | 0% $ 0 | |
| Independent Director | 5yrs | US$146.14k | 0% $ 0 | |
| Independent Director | 3.6yrs | US$157.14k | 0% $ 0 | |
| Independent Director | 5yrs | US$145.64k | 0% $ 0 | |
| Independent Director | 4.8yrs | US$145.64k | 0.076% $ 30.6k |
4.8yrs
Permanencia media
60yo
Promedio de edad
Junta con experiencia: La junta directiva de ANTX se considera experimentada (4.8 años de antigüedad promedio).